title: Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.
abstract: OBJECTIVE
  A novel device has been developed for measuring the cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. In this study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients.
  
  
  METHODS
  Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months. Before and after pitavastatin administration, HbA1c, serum lipids, serum malondialdehyde-LDL (MDA-LDL), urinary 8-hydroxy- 2'-deoxyguanosine (8-OHdG) and CAVI were measured.
  
  
  RESULTS
  After pitavastatin treatment for 12 months, significant decreases in 8-OHdG, MDA-LDL and CAVI were observed. DeltaCAVI significantly correlated with DeltaMDA-LDL.
  
  
  CONCLUSIONS
  In type 2 diabetic patients, pitavastatin may have an oxidative stress-reducing effect, especially in a state of enhanced oxidative stress, and CAVI may be useful as a routine test for the diagnosis and therapeutic monitoring of atherosclerosis.
authors.affiliation: Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, Japan. mumon@sf6.so-net.ne.jp
authors.forename: Yoh
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Kei
authors.initials: K
authors.lastname: Endo
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Saiki
authors.forename: Noriko
authors.initials: N
authors.lastname: Ban
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Kawana
authors.forename: Daiji
authors.initials: D
authors.lastname: Nagayama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohira
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Oyama
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000368:Aged; D000842:Ankle / Q000098:blood supply*; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D011673:Pulsatile Flow / Q000187:drug effects*; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008315:Malondialdehyde; D011804:Quinolines; C108475:pitavastatin